35 results on '"Berrou, Jeannig"'
Search Results
2. A multiparametric niche-like drug screening platform in acute myeloid leukemia
3. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells
4. Abstract 464: AAC-11 survival pathways as therapeutic target in cancer: AAC-11 leucine-zipper domain derived peptides exert potent antitumor effects and exhibit favorable stability, pharmacokinetic and toxicology profiles
5. Preclinical Evaluation of a Novel Small Molecule Inhibitor of LIM Kinases (LIMK) CEL_Amide in Philadelphia-Chromosome Positive (BCR::ABL+) Acute Lymphoblastic Leukemia (ALL)
6. Biological Effects of BET Inhibition by OTX015 (MK-8628) and JQ1 in NPM1-Mutated (NPM1c) Acute Myeloid Leukemia (AML)
7. Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer
8. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation
9. BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias
10. Abstract 608: The MPS1 inhibitor S81694 is active in acute myeloid leukemia (AML)
11. TYPE 1 PLASMINOGEN ACTIVATOR INHIBITORDEFICIENCY AGGRAVATES THE COURSE OF EXPERIMENTAL PASSIVE GLOMERULONEPHRITIS THROUGH TGF-BETA OVER ACTIVATION
12. Role of thrombin receptors in the kidney: lessons from PAR1 knock-out mice
13. Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)
14. Abstract 341: Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML)
15. Subtractive hybridization cloning: An efficient technique to detect overexpressed mRNAs in diabetic nephropathy
16. Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen
17. Combination of BCR-ABL1 Tyrosine Kinase Inhibitors with a Small Molecule LIM kinase1/2 Inhibitor in BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
18. Abstract 803: Bromodomain and extra-terminal BET inhibitors induce TP53 independent apoptosis, maturation and oncoprotein degradation in NPM1 mutated acute myeloid leukemia
19. Correction: Natural Killer Cell Function, an Important Target for Infection and Tumor Protection, Is Impaired in Type 2 Diabetes
20. Activity of OTX015 (MK-8628), a BET-Bromodomain Inhibitor, in Acute Myeloid Leukemia (AML) Progenitor Cells
21. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
22. Bromodomain Inhibition By OTX015 Regulates c-MYC and HEXIM1 in a Panel of Human Acute Leukemia Cell Lines
23. Preclinical Study Of The Bromodomain Inhibitor OTX015 In Acute Myeloid (AML) and Lymphoid (ALL) Leukemias
24. Natural Killer Cell Function, an Important Target for Infection and Tumor Protection, Is Impaired in Type 2 Diabetes
25. Natural Killer Cell Dysfunction in Uremia: The Role of Oxidative Stress and the Effects of Dialysis
26. NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients
27. Oxidative Stress Mediates a Reduced Expression of the Activating Receptor NKG2D in NK Cells from End-Stage Renal Disease Patients
28. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor β
29. Induction of Urokinase Receptor Expression in Nephrotoxic Nephritis
30. PROGNOSTIC VALUE OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 mRNA IN MICRODISSECTED GLOMERULI FROM TRANSPLANTED KIDNEYS1
31. Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1
32. Internalisation of the protease-activated receptor 1: Role of the third intracellular loop and of the cytoplasmic tail
33. Induction of Urokinase Receptor Expression in Nephrotoxic Nephritis.
34. PROGNOSTIC VALUE OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 mRNA IN MICRODISSECTED GLOMERULI FROM TRANSPLANTED KIDNEYS1.
35. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.